54824-17-8
Chemical Structure
Mitonafide
Synonym(s): NSC 300288
- CAS No.: 54824-17-8
- Formula:C16H15N3O4
- Molecular Weight:313.31
IUPAC Name: 2-(2-(dimethylamino)ethyl)-5-nitro-1H-benzo[de]isoquinoline-1,3(2H)-dione
InChIKey: XXVLKDRPHSFIIB-UHFFFAOYSA-N
SMILES: O=C1N(C(C2=CC([N+]([O-])=O)=CC3=CC=CC1=C23)=O)CCN(C)C
Biological Activity: Mitonafide (NSC 300288) is a cytostatic agent. Mitonafide binds to double-stranded DNA through intercalation, and inhibits DNA and RNA synthesis. Mitonafide is an antitumor agent that can be used in the research of cancers, such as non-small cell lung cancer (NSCLC), leukemia[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Mitonafide | 99.73% | Mitonafide (NSC 300288) is a cytostatic agent. Mitonafide binds to double-stranded DNA through intercalation, and inhibits DNA and RNA synthesis. Mitonafide is an antitumor agent that can be used in the research of cancers, such as non-small cell lung cancer (NSCLC), leukemia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mitonafide (Standard) | ≥98% | Mitonafide (Standard) is the analytical standard of Mitonafide. This product is intended for research and analytical applications. Mitonafide (NSC 300288) is a cytostatic agent. Mitonafide binds to double-stranded DNA through intercalation, and inhibits DNA and RNA synthesis. Mitonafide is an antitumor agent that can be used in the research of cancers, such as non-small cell lung cancer (NSCLC), leukemia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Llombart M, et al. Phase I study of mitonafide in solid tumors. Invest New Drugs. 1992 Aug;10(3):177-81. [Content Brief]
- [2]. inha BK, et al. Mechanism of DNA strand breaks by mitonafide, an imide derivative of 3-nitro-1,8-naphthalic acid. Biochem Pharmacol. 1985 Nov 1;34(21):3845-52. [Content Brief]
- [3]. Rosell R, et al. Phase I study of mitonafide in 120 hour continuous infusion in non-small cell lung cancer. Invest New Drugs. 1992 Aug;10(3):171-5. [Content Brief]
Keywords
